患者与肿瘤特征对早期乳腺癌来曲唑早期治疗持续性的影响:Evaluate-TM研究3941例结果
Evaluate-TM是一项前瞻性、多中心、非干预性研究,纳入3941例激素受体阳性早期乳腺癌绝经后女性,评估来曲唑辅助治疗的早期持续性。中位随访至15个月时,因非疾病进展停药事件540例(13.7%),其中多数(73.5%)为药物相关毒性;6、12、15个月持续性率分别为92.2%、86.9%、86.3%。影响提前停药的主要因素包括高龄(HR 1.02/年)、合并症(HR 1.06/每项合并症)、低体重指数和较低肿瘤分级(HR 0.85/每级)。
要点
- 来曲唑治疗6、12、15个月持续性率分别为92.2%、86.9%、86.3%。
- 非疾病进展停药事件540例(13.7%),其中73.5%为药物相关毒性。
- 高龄、合并症、低体重指数和低肿瘤分级与提前停药风险相关。
核心结论
- 高龄、多合并症、低肿瘤分级和低体重指数的患者停药风险最高,可能从依从性支持项目中获益。
研究设计与样本
- 前瞻性、多中心、非干预性研究,纳入3941例激素受体阳性早期乳腺癌绝经后女性,接受来曲唑辅助治疗。
- 在6个月和12个月两个预设访视点评估治疗持续性,以治疗开始至结束时间(TTEOT)为早期持续性指标,采用Cox回归分析患者和肿瘤特征对TTEOT的预测作用。
主要发现
- 全组3941例中,非疾病进展停药事件540例(13.7%),其中药物相关毒性占73.5%。
- 6、12、15个月持续性率分别为92.2%、86.9%、86.3%。
- 影响提前停药的主要因素:高龄(HR 1.02/年)、合并症(HR 1.06/每项合并症)、低体重指数和较低肿瘤分级(HR 0.85/每级)。
关键数值与推荐
- 持续性率:6个月92.2%,12个月86.9%,15个月86.3%。
- 停药事件:540/3941例(13.7%),其中药物相关毒性占73.5%。
- 风险比:高龄HR 1.02/年;合并症HR 1.06/每项合并症;肿瘤分级HR 0.85/每级。
临床怎么用
- 对于高龄、多合并症、低肿瘤分级和低体重指数的接受来曲唑辅助治疗的早期乳腺癌患者,可关注其治疗持续性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. PATIENTS AND METHODS: The EvAluate-TM study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase. Treatment persistence was evaluated at two pre-specified study visits after 6 and 12 months. As a measure of early therapy persistence the time from the start to the end of treatment (TTEOT) was analyzed. Cox regression analyses were carried out to identify patient characteristics and tumor characteristics predicting TTEOT. RESULTS: Out of the total population of 3941 patients with EBC, 540 (13.7%) events involving treatment cessation unrelated to disease progression were observed. This was due to drug-related toxicity in the majority of cases (73.5%). Persistence rates were 92.2%, 86.9%, and 86.3% after 6, 12, and 15 months, respectively. The main factors influencing premature treatment discontinuation were older age [hazard ratio (HR) 1.02/year], comorbidities (HR 1.06 per comorbidity), low body mass index, and lower tumor grade (HR 0.85 per grade unit). CONCLUSION: These results support the view that older, multimorbid patients with low tumor grade and low body mass index are at the greatest risk for treatment discontinuation and might benefit from compliance and support programs.
引用
- Nabieva N, Kellner S, Fehm T, et al. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann Oncol. 2018. PMID: 29045642. doi:10.1093/annonc/mdx630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。